Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 10, 2009, Pages 1587-1600

  Fock, K Ming ^a   Katelaris, Peter ^b   Sugano, Kentaro ^c   Ang, Tiing Leong ^a   Hunt, Richard ^d   Talley, Nicholas J ^e   Lam, Shiu Kum ^f   Xiao, Shu Dong ^g   Tan, Huck Joo ^h   Wu, Chun Ying ⁱ   Jung, Hyun Chae ^j   Hoang, Bui Huu ^k   Kachintorn, Udom ^l   Goh, Khean Lee ^m   Chiba, Tsutomu ⁿ   Rani, Abdul Aziz ^o  

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF SYDNEY   (Australia)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d MCMASTER UNIVERSITY   (Canada)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h Sunway Medical Centre   (Malaysia)

ⁱ TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^j Seoul National University   (South Korea)

^k HO CHI MINH CITY UNIVERSITY OF EDUCATION   (Viet Nam)

^l MAHIDOL UNIVERSITY   (Thailand)

^m UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

ⁿ KYOTO UNIVERSITY   (Japan)

^o CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

more..

Author keywords

H. pylori and gastric cancer; Helicobacter pylori:diagnosis; Helicobacter pylori:treatment and antimicrobial resistance

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; CANCER INCIDENCE; CANCER PREVENTION; CIGARETTE SMOKING; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DYSPEPSIA; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTESTINE ULCER; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; MEDICAL INFORMATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; OUTCOME ASSESSMENT; PEPTIC ULCER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY; STOMACH CANCER; TREATMENT DURATION; TREATMENT INDICATION;

EID: 68749089263     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05982.x     Document Type: Article

References (117)

1. Lam SK, Talley NJ. Report of the 1997 Asia-Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 1998 13 : 1 12.
2. Chey WD, Wong BC Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007 102 : 1808 1825.
3. Bourke B, Ceponis P, Chiba N et al. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents-an evidence-based evaluation. Can. J. Gastroenterol. 2005 19 : 399 408.
4. Caselli M, Zullo A, Maconi G et al. Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig. Liver Dis. 2007 39 : 782 789.
5. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
6. Shi R, Xu S, Zhang H. Prevalence and risk factors for Helicobacter pylori infection in Chinese populations. Helicobacter 2008 13 : 157 165.
7. Hoang TTH, Bengtsson C, Phung DC, Sorberg M, Granstro M. Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin. Diagn. Lab. Immunol. 2005 12 : 81 5.
8. Tan HJ, Goh KL. Changing epidemiology of Helicobacter pylori in Asia. J. Dig. Dis. 2008 9 : 186 189.
9. Yim JY, Kim N, Choi SH et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007 12 : 333 340.
10. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006 24 : 2137 2150.
11. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the cochrane systematic review of helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am. J. Gastroenterol. 2003 98 : 2621 2626.
12. Hsu PI, Lai KH, Lo GH et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002 51 : 15 20.
13. Fock KM, Talley N, Moayyedi P et al. Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. J. Gastroenterol. Hepatol. 2008 23 : 351 365.
14. Chiba N, van Zanten S, Sinclair P, Ferguson R, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002 324 : 1012 1016.
15. Mahadeva S, Chia YC, Vinothini A, Mohazmi M, Goh KL. Cost-effectiveness of and satisfaction with a Helicobacter pylori"test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia. Gut 2008 57 : 1214 1220.
16. Lane JA, Murray LJ, Noble S et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. BMJ 2006 332 : 199 204.
17. Sharma P, Wani S, Romero Y, Johnson D, Hamilton F. Racial and geographic issues in gastroesophageal reflux disease. Am. J. Gastroenterol. 2008 103 : 2669 2680.
18. Schwizer W, Thumshirn M, Dent J et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001 357 : 1738 1742.
19. Veldhuyzen van Zanten SJ, Bradette M, Chiba N et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can. J. Gastroenterol. 2005 19 : 285 303.
20. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001 121 : 1120 1126.
21. Hamada H, Haruma K, Mihara M et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment. Pharmacol. Ther. 2000 14 : 729 735.
22. Koike T, Ohara S, Sekine H et al. Increased gastric acid secrection after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment. Pharmacol. Ther. 2001 15 : 813 820.
23. Wu JCY, Chan FKL, Ching JYL et al. Effect of Helicobacter pylori eradication on treatment of gastrooesophageal reflux disease: a double blind, placebo controlled, randomized trial. Gut 2004 53 : 174 179.
24. Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J. Gastroenterol. 2005 40 : 1024 1028.
25. Tsukada K, Miyazaki T, Katoh H et al. The incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 2005 17 : 1025 1028.
26. Ishiki K, Mizuno M, Take S et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin. Gastroenterol. Hepatol. 2004 2 : 474 479.
27. Sasaki A, Haruma K, Manabe N, Tanaka S, Yoshihara M, Chayama K. Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. Aliment. Pharmcol. Ther. 2003 17 : 1529 1534.
28. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000 118 : 661 669.
29. Moayyedi P, Wason C, Peacock R et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000 5 : 206 214.
30. Katelaris PH. Gastro-oesophageal reflux disease and Helicobacter pylori. Minerva Gastroenterol. Dietol. 2003 49 : 235 241.
31. Mason JM, Raghunath AS, Hungin AP, Jackson W. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. Aliment. Pharmacol. Ther. 2008 28 : 1297 1303.
32. Hsu PI, Lai KH, Hsu PN et al. Helicobacter pylori infection and the risk of gastric malignancy. Am. J. Gastroenterol. 2007 102 : 725 730.
33. Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004 291 : 187 194.
34. Mera R, Fontham ET, Bravo LE et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005 54 : 1536 1540.
35. Sugano K. Prevention of gastric cancer: urgent need to implement Helicobacter pylori eradication therapy as a primary preventive measure in Japan. J. Gastroenterol. 2007 42 (Suppl. 17 1 2.
36. Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int. J. Cancer 2008 124 : 157 166.
37. Hunt R, Fallone C, Veldhuyzan van Zanten S et al. Update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can. J. Gastroenterol. 2004 18 : 547 554.
38. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008 372 : 350 352.
39. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
40. Roosendaal R, Kuipers EJ, Buitenwerf J et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am. J. Gastroenterol. 1997 92 : 1480 1482.
41. Leung WK, To KF, Chan FK, Lee TL, Chung SC, Sung JJ. Interaction of Helicobacter pylori eradication and non-steroidal anti-inflammatory drugs on gastric epithelial apoptosis and proliferation: implications on ulcerogenesis. Aliment. Pharmacol. Ther. 2000 14 : 879 885.
42. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 2001 344 : 967 973.
43. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2002 359 : 9 13.
44. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 2008 52 : 1502 1517.
45. Weil J, Langman MJ, Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000 46 : 27 31.
46. Loke YK, Trivedi AN, Singh S. Meta-analysis gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 2008 27 : 31 40.
47. Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract:. Indigestion and non-steroidal anti-inflammatory drugs. BMJ 2001 323 : 12369.
48. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 359 : 14 22.
49. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 2005 21 : 1411 1418.
50. Pounder RE. Helicobacter pylori and NSAIDs - the end of the debate? Lancet 2002 359 : 3 4.
51. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 310 : 827 830.
52. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 348 : 1413 1416.
53. Pilotto A, Franceschi M, Longoa MG et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig. Liver Dis. 2004 36 : 666 670.
54. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 2002 16 : 779 786.
55. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin. 2007 23 : 163 173.
56. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001 120 : 594 606.
57. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002 346 : 2033 2038.
58. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am. J. Gastroenterol. 2005 100 : 453 459.
59. Seo JK, Ko JS, Choi KD. Serum ferritin and Helicobacter pylori infection in children: a sero-epidemiologic study in Korea. J. Gastroenterol. Hepatol. 2002 17 : 754 757.
60. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2007 60 : 237 246.
61. Stasi R, Sarpatwari A, Segal JB et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 2009 113 : 1231 1240.
62. Perri F, Manes G, Neri M, Vaira D, Nardone G. Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. Am. J. Gastroenterol. 2002 97 : 2756 2762. (Pubitemid 35265425)
63. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment. Pharmacol. Ther. 2004 20 : 1001 1017.
64. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004 9 : 347 368.
65. Connor SJ, Seow F, Ngu MC, Katelaris PH. The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects. Aliment. Pharmacol. Ther. 1999 13 : 1287 1293.
66. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am. J. Gastroenterol. 1996 91 : 1138 1144.
67. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996 1 : 138 144.
68. Huang JQ, Chiba N, Wilkinson J, Hunt RH. Which combination therapy can eradicate > 90% Helicobacter pylon' infection? A meta-analysis of amoxicillin, metronidazole, tetracycline and clarithromycin containing regimes. Gastroenterology 1997 112 : A19.
69. Fock KM, Chelvam P, Lim SG. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment. Pharmacol. Ther. 2000 14 : 225 231.
70. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002 123 : 1763 1769.
71. Malfertheiner P, Bayerdörffer E, Diete U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther. 1999 13 : 703 712. (Pubitemid 29276838)
72. Zanten SJ, Bradette M, Farley A et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment. Pharmacol. Ther. 1999 13 : 289 295.
73. Wong BC, Chang FY, Abid S et al. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment. Pharmacol. Ther. 2000 14 : 1529 1535.
74. Zagari RM, Bianchi-Porro G, Fiocca R et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007 56 : 475 479.
75. Shimoyama T, Fukuda S, Mikami T et al. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol. 2004 39 : 927 930.
76. Kwok A, Walls R, Katelaris PH. Treating Helicobacter pylori infected patients who have a history of penicillin allergy: a role for immunological testing. Aliment. Pharmacol. Ther. 2009 in press).
77. Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 2007 45 : 4006 4010.
78. Kim JJ, Reddy R, Lee M et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J. Antimicrob. Chemother. 2001 47 : 459 461. (Pubitemid 32303414)
79. Kim JM, Kim JS, Jung HC et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 2004 48 : 4843 4847.
80. Cheng H, Hu FL The epidemiology of Helicobacter pylori resistance to antibiotics in Beijing. Zhonghua Yi Xue Za Zhi 2005 85 : 2754 2757.
81. Ling TK, Cheng AF, Sung JJ et al. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1996 1 : 57 61.
82. Wang WH, Wong BC, Mukhopadhyay AK et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment. Pharmacol. Ther. 2000 14 : 901 910.
83. Huang AH, Sheu BS, Yang HB et al. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole based triple therapy. J. Formos. Med. Assoc. 2000 99 : 704 709.
84. Hu CT, Wu CC, Lin CY et al. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J. Gastroenterol. Hepatol. 2007 22 : 720 723.
85. Thyagarajan SP, Ray P, Das BK et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J. Gastroenterol. Hepatol. 2003 18 : 1373 1378.
86. Choi YS, Cheon JH, Lee JY et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J. Gastroenterol. 2006 48 : 156 161.
87. Graham DY, Lu H, Yamaoka Y A report card to grade Helicobacter pylori therapy. Helicobacter 2007 12 : 275 278.
88. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment. Pharmacol. Ther. 2007 26 : 343 357.
89. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: Duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 2007 147 : 553 562.
90. Kim BG, Lee DH, Ye BD et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007 12 : 31 5.
91. Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. 2003 17 : 1137 1143. (Pubitemid 36605750)
92. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 2003 98 : 562 567.
93. Jafri N, Hornung CA, Howden CW. Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 2008 148 : 1 10.
94. Choi WH, Park DI, Oh SJ et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J. Gastroenterol. 2008 51 : 280 284.
95. Nagahara A, Miwa H, Kawabe M et al. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. J. Gastroenterol. 2004 39 : 1051 1055.
96. Matsuhisa T, Kawai T, Masaoka T et al. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter 2006 11 : 152 158.
97. Magaret N, Burm M, Faigel D et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig. Dis. 2001 19 : 174 178.
98. Ang TL, Fock KM, Ng TM et al. Efficacy of quadruple therapy for Helicobacter pylori eradication after failure of proton pump inhibitor-based triple therapy in Singapore. Chin. J. Dig. Dis. 2003 4 : 35 9.
99. Dore MP, Graham DY, Melee R et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 2002 97 : 857 860.
100. Lin CK, Hsu PI, Lai KH et al. One-week quadruple therapy is an effective salvage regimen for helicobacter pylori infection in patients after failure of standard triple therapy. J. Clin. Gastroenterol. 2002 34 : 547 551.
101. Zheng Q, Dai J, Li XB, Lu H, Xiao SD. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infection: a single-center, randomized, open and parallel-controlled study. Chin. J. Gastroenterol. 2009 14 : 8 11.
102. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. 2006 23 : 35 44.
103. Rossi R, Jabes D, Della Bruna C. In vitro activity of rifabutin, a potential antibiotic in the therapy of Helicobacter pylori. Abstract Book of the 6th International Congress for Infectious Diseases, Prague (Czech Republic) 1994 F, Festa V, Clemente R et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. 2001 96 : 58 62.
104. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J. Clin. Gastroenterol. 2000 31 : 222 225.
105. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment. Pharmacol. Ther. 2007 26 : 1537 1542.
106. Gonzalez Carro P, Perez Roldan F, De Pedro Esteban A et al. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J. Gastroenterol. Hepatol. 2007 22 : 60 3.
107. Navarro-Jarabo JM, Fernandez N, Sousa FL et al. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. BMC Gastroenterol. 2007 7 : 31.
108. Gisbert JP, Gisbert JL, Marcos S et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment. Pharmacol. Ther. 2006 15 : 1469 1474.
109. Miehlke S, Schneider-Brachert W, Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008 13 : 69 74.
110. Wong WM, Gu Q, Lam SK et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. Quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2003 17 : 553 560.
111. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 2006 101 : 1467 1475.
112. Sheu BS, Kao AW, Cheng HC et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment. Pharmacol. Ther. 2005 21 : 283 288.
113. Kang JM, Kim N, Lee DH et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J. Gastroenterol. Hepatol. 2008 23 : 1287 1291.
114. Sheu BS, Fock KM. CYP2C19 genotypes and Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 2008 23 : 1163.
115. Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 4.
116. Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med. 2006 119 : 217 224.
117. Matsuo K, Hamajima N, Ikehara Y et al. Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin. Epidemiol. Infect. 2003 130 : 227 233.